The first approved drug to slow the progression of the illness will come with a strong safety warning about potentially life-threatening side effects.
The first approved drug to slow the progression of the illness will come with a strong safety warning about potentially life-threatening side effects.
I’m extremely curious, and would love to read the research on this. The amyloid scandal last year finally forced the field of AD research to confront how weak this hypothesis is (we all exhibit plaques and tangles in aging, it’s not unique to AD), however this medication seems to target that exact mechanism. Especially with the incidences of brain swelling and bleeds being relatively high in the treatment group, it’s a questionable approach.
People have sunk their entire careers into beta amyloid research, and so many labs sadly seem to be fighting for this as the status quo instead of being willing to admit they’re engaging in a sunken cost fallacy.